Hydroxyurea (Hydroxycarbamide)

Hydroxycarbamide (hydroxyurea) blocks the enzyme ribonucleotide reductase, which is essential for DNA synthesis. By limiting the supply of deoxyribonucleotides, it slows the growth of rapidly dividing cells such as malignant leukemic cells and over‑producing blood cells, providing therapeutic benefit in the indicated disorders.

The dose of Hydroxyurea is individualized and set by the prescribing healthcare professional based on the specific indication, patient weight, renal and hepatic function, and response to therapy. No standard dose is provided here; patients should follow the prescriber’s instructions.

Hydroxyurea is classified as pregnancy category D, meaning it may cause fetal harm and should be avoided unless the potential benefit justifies the risk. It is also not recommended during breastfeeding because it can be excreted in milk and may affect the infant.

To place an order, submit an enquiry on the Hydroxyurea product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Hydroxyurea is a cytoreductive oral agent, often preferred for its ease of administration compared with injectable therapies such as interferon‑alpha or ruxolitinib. While it effectively reduces cell proliferation, alternative drugs may offer different safety profiles or mechanisms, so the choice depends on disease severity, patient tolerance, and clinician judgment.

Hydroxyurea tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Hydroxyurea is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing and any dietary considerations to ensure consistent absorption.

The most serious adverse events include severe bone‑marrow suppression leading to life‑threatening neutropenia or aplastic anemia, acute renal failure, and pulmonary toxicity such as interstitial pneumonitis. Patients should be monitored regularly for blood counts, kidney function, and respiratory symptoms.

Hydroxyurea is contraindicated in patients with known hypersensitivity to the drug, those with severe pre‑existing bone‑marrow suppression, and pregnant women unless the therapeutic benefit outweighs the risk. Caution is also advised for individuals with significant renal or hepatic impairment.